Tongxinluo preserves the renal function in diabetic kidney disease via protecting the HK-2 cells from the patterns of programmed cell death

Keywords: Apoptosis, Diabetes, HK-2 cell, Kidney disease, Programmed cell death, Pyroptosis, Renal tubular injury, Tongxinluo


This study was explored the renoprotective effect of Tongxinluo (a Traditional Chinese Medicine) on diabetic kidney disease and its underlying mechanism. The results revealed significant (p<0.05) up-regulation of the expression of Bcl-2 and down-regulation of NF-κB p-p65, ASC, NLRP3, caspase-1, cleaved GSDMD, IL-1β, caspase-3, Bax and the ratio of Bcl-2 and Bax in immortalized proximal tubular HK-2 cells cultured by hyperglycemia combined with hyperlipidemia. In db/db mice, Tongxinluo treatment substantially decreased the 24 hours albuminuria excretion rate and the urine albumin-creatinine ratios and renal morphologic abnormalities. Similarly, the levels of NF-κB p-p65, NLRP3, caspase-1, cleaved GSDMD, IL-1β, caspase-3, and the ratio of Bcl-2 and Bax were down-regulated by Tongxinluo treatment in the kidney samples of db/db mice (p<0.05). Taken together, according to the anti-pyroptosis and anti-apoptosis effect of Tongxinluo, it shows the potential to be effective for the treatment of diabetic kidney disease.


Download data is not yet available.

Author Biography

Yiling Wu, Nanjing University of Chinese Medicine, Nanjing 210046, China.



Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018; 14: 361-77.

Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020; 21: 678-95.

Chen WQ, Zhong L, Zhang L, Ji XP, Zhao YX, Zhang C, Jiang H, Wu YL, Zhang Y. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. J Ethnopharmacol. 2009; 124: 103-10.

Chen Y, Li M, Zhang Y, Di M, Chen W, Liu X, Yu F, Wang H, Zhen X, Zhang M. Traditional Chinese medication Tongxinluo attenuates apoptosis in ox-LDL-stimulated macrophages by enhancing Beclin-1-induced autophagy. Biochem Biophys Res Commun. 2018; 501: 336-42.

Frank D, Vince JE. Pyroptosis versus necroptosis: Similarities, differences, and crosstalk. Cell Death Differ. 2018; 26: 99-114.

Davis RC, Castellani LW, Hosseini M, Ben-Zeev O, Mao HZ, Weinstein MM, et al., Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 2010; 59: 1616-25.

Endo H, Owada S, Inagaki Y, Shida Y, Tatemichi M. Glucose starvation induces LKB1-AMPK-mediated MMP-9 expression in cancer cells. Sci Rep. 2018, 8: 10122.

Epstein FH, Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998; 339: 1448-56.

Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From mechanisms of action to therapies. Cell Metab. 2014; 20: 953-66.

Gilbert RE. Proximal tubulopathy: Prime mover and key therapeutic target in diabetic kidney disease. Diabetes 2017; 66: 791-800.

Hua W, Huang HZ, Tan LT, Wan JM, Gui HB, Zhao L, Ruan XZ, Chen XM, Du XG. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PloS one. 2015; 10: e0127507.

Hutton HL, Ooi JD, Holdsworth SR, Kitching AR. The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology 2016; 21: 736-44.

Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011; 6: 395-423.

Kim YJ, Kim YA, Yokozawa T. Pycnogenol modulates apoptosis by suppressing oxidative stress and inflammation in high glucose-treated renal tubular cells. Food Chem Toxicol. 2011; 49: 2196-201.

Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT. The role of HIF-1α in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem. 2003; 278: 40296-304.

Li S, Zheng L, Zhang J, Liu X, Wu Z. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. Free Radic Biol Med. 2021; 162: 435-49.

Mitchell PL, Nachbar R, Lachance D, St-Pierre P, Trottier J, Barbier O, et al. Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice. Diabetes Metab. 2017; 19: 313-19.

Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J. Targeting inflammation in diabetic nephropathy: A tale of hope. Expert Opin Investig Drugs. 2018; 27: 917-30.

Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review. Diabetologia 2006; 49: 434-41.

Pyo JS, Kim HH, Kim KM, Kang JS. Amelioration of dry eye syndrome by oral administration of cultivated wild ginseng extract. Bangladesh J Pharmacol. 2019; 14: 61-66.

Qi K, Li L, Li X, Zhao J, Wang Y, You S, Hu F, Zhang H, Cheng Y, Kang S, Cui H. Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury. PloS one. 2015; 10: e0119846.

Qi K, Li X, Geng Y, Cui H, Jin C, Wang P, Li Y, Yang Y. Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway. PloS One. 2018; 13: e0198403.

Qin G, Huang F, Wang Q, Guo F, He Y. FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease. SSRN Electronic J. 2019; 48: 491-504.

Qiu YY, Tang LQ. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharm Res. 2016: 251-64.

Robinson N, Ganesan R, Hegeds C, Kovács K, Virág L. Programmed necrotic cell death of macrophages: Focus on pyrop-tosis, necroptosis, and parthanatos. Redox Biol. 2019; 26: 2213-317.

Sembach FE, Østergaard MV, Vrang N, Feldt-Rasmussen B, Fosgerau K, Jelsing J, Fink LN. Rodent models of diabetic kidney disease: Human translatability and preclinical validity. Drug Discov Today. 2020; 2020.

Stockwell BR, Angeli JPF, Bayir H. Ferroptosis: A regulated cell death nexus linking metabolism. Redox Biol Dis Cell. 2017; 171: 273-85.

Tesch GH, Lim AKH. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephro-pathy. Am J Physiol Renal Physiol. 2011; 300: 301-10.

Wang JY, Gao YB, Zhang N, Zou DW, Xu LP, Zhu ZY, Li JY, Zhou SN, Cui FQ, Zeng XJ, Geng JG. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy. Am J Physiol. Renal Physiol. 2014; 306: F486-95.

Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, Beck PL. Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium. J Immunol. 2013; 190: 1239-49.

Wang Y, Bi R, Quan F, Cao Q, Zhang D. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. Eur J Pharmacol. 2020; 888: 173574.

Wu T, Harrison RA, Chen XY, Ni J, Zhou L, Qiao J, Wang Q, Wei J, Duan X, Zheng J. Tongxinluo (Tong xin luo or Tong‐xin‐luo) capsule for unstable angina pectoris. Cochrane Database Syst Rev. 2006.

Wu XM, Gao YB, Cui FQ, Zhang N. Exosomes from high glucose-treated glomerular endothelial cells activate mesan-gial cells to promote renal fibrosis. Biol Open. 2016; 5: 484-91.

Yuan GQ, Wu YL, Jia ZH. Experimental study on effect of Tongxinluo on nerve cell apoptosis after cerebral ischemia in middle cerebral arterial obstructive model rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007; 27: 720-23.

Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017; 30: 701-17.

Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, Wang R, Liu CX, Feng JB, Jiang H, Xu XS. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: A comparison with a high-dose simvastatin therapy. Am J Physiol Heart C. 2009; 297: H2004-14.

Zhang M, Liu Y, Xu M, Zhang L, Liu X, Zhao Y, Zhu F, Xu R, Ou Z, Wang Y, Liu Q. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study. Sci Rep. 2019; 9: 4545.

Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol. 2011; 22: 1668-81.

How to Cite
Shen, S., Y. Hou, and Y. Wu. “Tongxinluo Preserves the Renal Function in Diabetic Kidney Disease via Protecting the HK-2 Cells from the Patterns of Programmed Cell Death”. Bangladesh Journal of Pharmacology, Vol. 16, no. 2, Apr. 2021, pp. 52-64, doi:10.3329/bjp.v16i2.52090.
Research Articles